Principal Inventor of Rheoxtech therapy-Multiple US Patents issued
Veteran Cardiac Surgeon-Board Certifications (General, Vascular, Thoracic Surgery)
Cardiovascular Epidemiologist
Former Attending Cardiac Surgeon Northwestern Medicine
Former Consulting Staff, Cleveland Clinic Foundation
Harvard School of Public Health-MPH 2024. Masters Focusing on Epidemiology and Quantitative Methods
Rush Medical College-Doctorate of Medicine

Founder and former CEO, Defibtech (acquired by Nihon Kohden); Defibtech has sold over 500,000 defibrillators and millions of consumables worldwide
40+ patents, led products through 10+ FDA 510(k) and CE Mark approvals
Products have won numerous design awards, including Medical Device Excellence Awards - MDEA (2005, 2011, 2016), Industrial Design Excellence Award – IDSA (2004, 2010, 2011)
B.S., Engineering, Yale Univ.

Multiple board certifications: Interventional Cardiology, Cardiovascular Disease, Echocardiography
Over 15+ peer-reviewed publications and academic presentations
Extensive research background in cell biology, biochemistry and molecular biophysics.
MD, Northwestern University Feinberg School of Medicine
PhD, Biomedical Sciences, University of Texas Southwestern Medical Center
BS, Biomedical Engineering, Duke University

Veteran Medical Device Quality and Regulatory professional
30+ years of experience including Physio-Control (Medtronic/Stryker), Defibtech, Innoblative
Numerous regulatory approvals: PMA, IDE, 8 FDA 510(k)s and 8 CE Marks
Designed, implemented, and managed quality systems within companies ranging from start ups to larger companies
BS, Electrical Engineering, Gonzaga University

Surgeon entrepreneur with multiple successful exits in medtech as co-founder, CEO, CMO, board advisor, and board member. These include SIA (founding CEO), RapidRona (co-founder/CMO), Atraverse (Board Advisor), and counting. At SIA, managed the company through parallel pathway of commercializing a 510k device while running a clinical program for a PMA device in the same market.

- CEO, Amsel Medical.
Raised over $20M in investment and grants. Led development of world’s first percutaneous, vessel-specific tourniquet for junctional hemorrhage
- Executive, AngioDynamics (17 years). Guided the company through successful IPO. Led development of the gold standard endovenous laser system for the treatment of superficial venous disease.
Multiple acquisitions & integrations
- Vice President, American Venous Forum Foundation